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Abstract
Background: Bipolar disorder is a lifelong episodic condition characterized by mood swings
between mania and depression. Several lines of evidence suggest that serotonin is likely to play a
pivotal role in the pathophysiology of bipolar disorder. Ritanserin, a 5-HT2 receptor antagonist, has
been reported to have antipsychotic activity. In this 6-week double blind, placebo controlled study
involving moderate to severe manic patients, we assessed the effects of ritanserin plus haloperidol
in combination with lithium.
Methods: 45 patients aged between 21–43 were eligible to participate as they met the DSM-IV
criteria for a current manic episode, on the basis of a clinical interview by an academician
psychiatrist. In addition, a score of at least 20 points on the Young Mania rating Scale was required
representing moderate to severe mania. Patients were randomly allocated lithium (1–1.2 mEq/L) +
haloperidol (10 mg/day)+ ritanserin (10 mg/day) (Group A) or lithium (1–1.2 mEq/L)+ haloperidol
(10 mg/day) + placebo (Group B) for a 6-week, double-blind, placebo-controlled study. Patients
were assessed by a third year psychiatry resident at baseline and 3, 7, 14, 21, 28 and 42 days after
the medication started. All patients entered the hospital were not previously under any medication.
The mean decrease in the Young Mania Rating Scale score from baseline was used as the main
outcome measure of response of mania to treatment. The extrapyramidal symptoms were
assessed using the Extrapyramidal Symptoms Rating Scale. Side effects were systematically
recorded throughout the study and were assessed using a checklist.
Results: Young Mania Rating Scale total scores improved with ritanserin. The difference between
the two protocols was significant as indicated by the effect of group and the between-subjects
factor (F = 5.02, d.f. = 1, P = 0.03). The means Extrapyramidal Symptoms Rating Scale scores for
the placebo group were higher than the ritanserin group and the difference was significant in day
42. The difference between the two groups in the frequency of side effects was not significant
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Conclusions: The efficacy of ritanserin to obtain a better improvement in patients with mania
seems to support the 5-HT hypothesis of bipolar disorder.
Background
Bipolar disorder is a lifelong episodic condition character-
ized by mood swings between mania and depression. The
lifetime prevalence of bipolar disorder to be 0.8. The 1
month point prevalence for bipolar disorder has been
estimated as 0.4%. Acute manic episodes can have devas-
tating consequences [1]. Management of acute mania is
directed at rapidly controlling the irritability, agitation,
impulsivity, aggression, and psychotic symptoms that
characterize the hyperaroused state in manic and mixed
episodes. It is recognized that in the clinical treatment of
mania, a substantial number of patients do not respond
or are partial respondents to therapy, and hence, have a
poor outcome. Lithium remains the first line-choice treat-
ment for patients with mania. However, nearly half of
patients with mania fail to respond to lithium. In fact, fail-
ure rates as high as 72% to 80% have been reported for
those treated with lithium [2]. Because rapid control of
acute mania is desired, adjunctive agents, including com-
bination of two mood stabilizers or of a mood stabilizer
with an antipsychotic agent, are widely used [3]. Typical
neuroleptics have been suggested to be superior in efficacy
to lithium monotherapy. However, they do not have a
large role in maintenance therapy, though, because of side
effects such as extrapyramidal symptoms and tardive dys-
kinesia [4–6]. Atypical antipsychotics such as risperidone
and olanzepine have also been used to treat bipolar disor-
der. Initial reports suggest that risperidone and olan-
zepine, when combined with mood-stabilizing agents,
exhibits mood stabilizing or antimanic activity [7].
Several lines of evidence suggest that serotonin is likely to
play a pivotal role in the Pathophysiology of bipolar dis-
order. The significant observation on which this hypothe-
sis is base are: (1) absolute levels of the 5-HT metabolites
(5-HIAA) are reduced in CSF of depressed bipolar patients
and raised in mania. (2) 5-HT transport is reduced in
platelets of depressed bipolar patients as well as platelets
of bipolar patients in manic phase [8]. A rapidly growing
body of data suggests that dysfunction in serotonergic
functions may be involved in the pathophysiology of
schizophrenia and bipolar disorder [8,9], and that phar-
macological agents for these illnesses have their therapeu-
tic effects mediated through serotonergic mechanisms.
One of the first indications that 5-HT2 receptor antago-
nists may possess antipsychotic potential came from Ceu-
lemans et al who found setoperone to be effective in
reducing autistic behavior, dysphoric mood, hallucina-
tion and EPS [10]. Ritanserin a 5-HT2 receptor antagonist
has been reported to have antipsychotic activity [11].
In several double-blind, placebo-controlled studies, the
efficacy of ritanserin and cyproheptadine were evaluated
in the treatment of schizophrenia [11,12]. In add-on pro-
tocol, ritanserin and cyproheptadine were effective in con-
current treatment of negative symptoms and reduction of
EPS. Beneficial effects of Ritanserin have also been dem-
onstrated in antipsychotic-induced akathisia or when
compared with anticholinergic agents. The efficacy of
Ritanserin with its pharmacological profile as a 5-HT2
antagonist is line with 5-HT hypothesis of schizophrenia
[13–18].
Therefore, in this 6-week double blind, placebo control-
led study involving moderate to severe manic patients, we
assessed the effects of ritanserin plus haloperidol in com-
bination with lithium. To our knowledge, this study is the
first clinical trial assessing the adjunctive role of ritanserin
in the management of mania
Methods
Trial organization
This was a 6 week, parallel group, placebo controlled trial
undertaken in Roozbeh Psychiatric Hospital, Tehran, Iran
during January 2002-January 2003.
Participants
Eligible participations were 45 in patient, age between
21–43 years old and met DSM-IV criteria for a current
manic episode, on the basis of a clinical interview by an
academician psychiatrist. In addition, a score of at least 20
points on the Young Mania rating Scale [19] was required
representing at least a moderate to severe mania. Mental
retardation, neurological or other medical impairment,
the need for ongoing treatment with other psychoactive
medications, and/or current substance dependence, sei-
zure disorder requiring medication, participation in an
investigational drug trial within 30 days before the start of
the trial, known sensitivity to haloperidol, lithium or
ritanserin, use of clozapine within 1 month before study
entry; use of depot neuroleptics within one cycle before
study entry, laboratory values outside the normal range,
women of childbearing potential who were without ade-
quate contraception were exclusionary criteria. The trial
was performed in accordance with the Declaration of Hel-
sinki and subsequent revisions and approved by ethics
committee at Tehran University of Medical Sciences. Writ-
ten informed consents were obtained before entering into
the study.BMC Psychiatry 2003, 3 http://www.biomedcentral.com/1471-244X/3/7
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Study design
All patients entered the hospital untreated with any med-
ications. Patients were randomly allocated 23 to lithium +
haloperidol+ ritanserin (Group A) or lithium + haloperi-
dol + placebo (Group B) for a 6-week, double-blind, pla-
cebo-controlled study. Two patients from group A and
one from group B dropped out from the study leaving 42
patients who met the DSM-IV criteria for manic episode.
Rapid titration of lithium to therapeutic level 1–1.2 mEq/
L was facilitated by the use of the pharmacokinetic
method of predicting a therapeutic dose. Weekly lithium
levels were obtained for compliance monitoring. Adjunc-
tive antipsychotic medication that was haloperidol and
was started simultaneously with lithium. The dose of
haloperidol was titrated up to 10 mg/day. A fixed dose of
ritanserin 10 mg/day was used throughout the study.
Concomitant lorazepam use was restricted to a maximum
dose of 2 mg/day for the first 4 days of treatment and
thereafter by up to 1 mg/day for the next 6 days.
Lorazepam was not permitted beyond the initial 10 days
and was not allowed within 8 hours of the administration
of mania rating scale. Biperiden was permitted to treat
extrapyramidal symptoms up to a maximum of 6 mg/day
throughout the course of the study. Biperiden was not
allowed as prophylaxis for extrapyramidal symptoms.
Patients were assessed by a third year resident of psychia-
try at baseline and after 3, 7, 14, 21, 28 and 42 days after
the medication started. Patients were hospitalized
throughout the study.
Outcome
The principal measure of the outcome was the Young
Mania Rating Scale. The rater used standardized instruc-
tions in the use of Young Mania Rating Scale. The mean
decrease in Young Mania Rating Scale score from baseline
was used as the main outcome measure of response of
mania to treatment. The extrapyramidal symptoms were
assessed using the Extrapyramidal Symptoms Rating Scale
(ESRS) [20]. Patients were randomized to receive ritan-
serin or placebo in a 1: 1 ratio using a computer generated
code. The assignments were kept in sealed, opaque enve-
lopes until the point of allocation.
Side effects
Side effects were systematically recorded throughout the
study and were assessed using a checklist administered by
a resident of psychiatry on day 3, 7, 14, 21, 28 and 42
(Table 3).
Statistical analysis
A two-way repeated measures analysis of variance (time-
treatment interaction) was used. The two groups as a
between-subjects factor (group) and the seven measure-
ments during treatment as the within-subjects factor
(time) were considered. This was done for Young Mania
Rating Scale scores. In addition, a one-way repeated meas-
ures analysis of variance with a two-tailed post-hoc Tukey
mean comparison tests were performed on the change
Mania Rating Scale scores from baseline. To compare the
reduction of score of Young Mania Rating Scale at week 6
compared to baseline and ESRS score in different days an
unpaired two-sided Student's t-test was used. Results are
presented as mean ± SD differences and were considered
significant with P = 0.05. To compare the baseline data
and frequency of side effects between the protocols,
Fisher's exact test was performed. A traditional "observed
cases" (OC, the patients who completed the trial) analysis
in 42 days was the primary efficacy analysis. In addition,
intention to treat (ITT) analysis with last observation car-
ried forward (LOCF) procedure was also performed. All
results discussed are based on OC analysis unless other-
wise stated.
Results
65 patients were screened for the study. Twenty patients
were excluded before or during run in due to exclusion cri-
teria and 45 were randomized to trial medication. No sig-
nificant differences were identified between patients
randomly assigned to the group A or B condition with
regard to basic demographic data including age and gen-
der (Table 1). In addition, there were no significant differ-
ences in terms of duration of illness and number of
hospitalization in the both groups. 42 patients completed
the trial. In the group A and B the number of dropouts
were 2, and 1, respectively (Figure 1).
Ritanserin vs placebo
The mean ± SD scores of two groups of patients are shown
in Figure 2. There were no significant differences between
the two groups in day 0 (baseline) on the Young Mania
rating Scale (t = 0.81, d.f. = 43, P = 0.81). The difference
between the two protocols was significant as indicated by
the effect of group, the between-subjects factor (F = 5.02,
d.f. = 1, P = 0.03; F = 5.11, d.f. = 1, P = 0.029 for OC and
LOCF respectively). The behavior of the two treatments
was homogeneous across the time (groups-by-time inter-
action, Greenhouse-Geisser correction; F = 1.71, d.f. =
2.85, P = 0.17). In addition, a one-way repeated measures
analysis of variance showed a significant effect of both
protocols on the Young Mania rating Scale (P < 0.0001).
In both groups post-hoc comparisons showed a signifi-
cant change from day 3 on the Young Mania rating Scale.
The difference between the two protocols was significant
at the endpoint (day 42) (t = 3.56, d.f. = 40, P < 0.001).
The changes at the endpoint compared to baseline were: -
22 ± 4.47 (mean ± SD) (the baseline score was 25.38 ±
3.17) and -19.33 ± 5.06 (the baseline score was 26 ± 3.58)
for group A and B respectively. A significant difference was
observed on the change of scores of the Young ManiaBMC Psychiatry 2003, 3 http://www.biomedcentral.com/1471-244X/3/7
Page 4 of 7
(page number not for citation purposes)
Trial profile Figure 1
Trial profile
Table 1: Baseline data
Lithium+Haloperidol+Ritanserin Lithium+Haloperidol+Placebo P
Age (mean ± SD) 29.69 ± 6.03 28.22 ± 6.10 0.42
Gender Male: 14, Female: 9 Male: 15, Female: 7 0.75
20 excluded before or during run in 
23 assigned to Ritanserin  22 assigned to Placebo 
2 discontinued: 
  1consent withdrawn
  1 ineligible to continue 
1 discontinued:
     ineligible to continue 
21 completed trial  21completed trial 
45 randomized
65 patients screened 
Figure 1 Trial profile BMC Psychiatry 2003, 3 http://www.biomedcentral.com/1471-244X/3/7
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rating Scale in day 42 compared to baseline in the two
groups in (t = 2.09, d.f. = 40, P < 0.042).
Extrapyramidal Symptoms Rating Scale
The means ESRS for the placebo group were higher than
the ritanserin group and the difference was significant in
day 42. (Table 2). A not quite significant difference was
observed between the overall mean biperiden dosage in
the two groups. (106 ± 46.89 and 143 ± 56.18 for group
A and B respectively (mean ± SD) (P = 0.06).
Clinical complications and side effects
Seventeen side effects were observed over the trial. The dif-
ference between the two groups in the frequency of side
effects was not significant (Table 3).
Discussion
The present study shows Young Mania Rating Scale total
scores improved with ritanserin over this 6-week double
blind and placebo controlled trial. In addition, ESRS total
scores at endpoint were significantly higher in patients
who received only lithium and haloperidol. Total mean
antiparkinsonian medication was also higher in this
group. There is enough convincing Preclinical and clinical
evidence to suggest that 5-HT2A  receptor function is
altered in patients with bipolar disorder and schizophre-
nia [8,9]. Serotonin modulation of dopaminergic func-
tion via 5-HT2A receptors may provide a viable mechanism
for enhancing medications for bipolar disorder and schiz-
ophrenia. Therefore, potent 5-HT2A receptor antagonism
alone may contribute action of several clinically effective
antipsychotics that have a reduced extrapyramidal symp-
toms liability [8,9,13,14]. The efficacy of ritanserin to
obtain a better improvement in patients with mania
seems to support this hypothesis.
The limitations of the present study, including the small
number of patients should be considered so further
research in this area is needed. Finally the results demon-
strate that the combination of ritanserin with lithium and
a conventional antipsychotic was superior to lithium and
conventional antipsychotic alone for the rapid reduction
of manic symptoms. The combined use of ritanserin with
Table 2: Extrapyramidal symptoms based on Extrapyramidal Symptoms Rating Scale
Mean ± SEM Lithium + Haloperidol+ Ritanserin Mean ± SEM Lithium + Haloperidol+ Placebo P
Day 0 1.70 ± 0.17 1.80 ± 0.44 0.83
Day 3 2.30 ± 0.44 2.35 ± 0.42 0.93
Day 7 2.30 ± 0.20 2.80 ± 0.33 0.21
Day 14 2.65 ± 0.28 3.05 ± 0.40 0.42
Day 21 2.00 ± 0.24 2.85 ± 0.37 0.18
Day 28 1.95 ± 0.22 3.00 ± 0.49 0.059
Day 42 1.50 ± 0.17 3.00 ± 0.39 0.001***
Table 3: Number of patients with side effects
Side Effects Lithium + Haloperidol + Ritanserin Lithium + Haloperidol + Placebo P
Asthenia 10 (47.60%) 7 (33.33%) 0.53
Agitation 8 (38.09%) 13 (61.90%) 0.21
Constipation 5 (23.80%) 6 (28.50%) 1.00
Diarrhea 1 (4.76%) 2 (9.52%) 1.00
Dizziness 9 (42.85%) 6 (28.57%) 0.52
Dry Mouth 12 (57.14%) 15 (71.42%) 0.52
Dyspepsia 6 (28.57%) 5 (23.80%) 1.00
Headache 5 (23.80%) 4 (19.04%) 1.00
Increased Appetite 18 (85.71%) 16 (76.19%) 0.69
Nervousness 8 (38.09%) 12 (57.14%) 0.35
Pain 5 (23.80%) 3 (14.28%) 0.69
Sleep Disorder 6 (28.57%) 4 (19.04%) 0.71
Somnolence 14 (66.66%) 17 (80.95%) 0.48
Vomiting 1 (4.76%) 2 (9.52%) 1.00
Weight Gain 19 (90.47%) 16 (76.19%) 0.40BMC Psychiatry 2003, 3 http://www.biomedcentral.com/1471-244X/3/7
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lithium and haloperidol was well tolerated in these
acutely manic patients.
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